专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO0203917A3 ALPHAVIRUS VECTORS AND VIROSOMES WITH MODIFIED HIV GENES FOR USE AS VACCINES 审中-公开
标题翻译：具有修饰的HIV基因的野生型病毒和病毒用作疫苗
公开(公告)号：WO0203917A3
公开(公告)日：2002-08-29
申请号：PCT/US0121701
申请日：2001-07-09
申请人： ALPHAVAX INC , UNIV NORTH CAROLINA , OLMSTED ROBERT , KEITH PAULA , DRYGA SERGEY , CALEY IAN , MAUGHAN MAUREEN , JOHNSTON ROBERT , DAVIS NANCY , SWANSTROM RONALD
发明人： OLMSTED ROBERT , KEITH PAULA , DRYGA SERGEY , CALEY IAN , MAUGHAN MAUREEN , JOHNSTON ROBERT , DAVIS NANCY , SWANSTROM RONALD
IPC分类号： A61K39/00 , A61K39/21 , C07K14/16 , C07K14/18 , C12N7/02 , A61K39/12
CPC分类号： C07K14/005 , A61K39/00 , A61K39/12 , A61K39/21 , A61K2039/5256 , A61K2039/54 , A61K2039/545 , A61K2039/57 , C12N7/00 , C12N2740/16034 , C12N2740/16122 , C12N2740/16134 , C12N2740/16222 , C12N2740/16234 , C12N2770/36143 , C12N2770/36151
摘要： The present invention provides methods and compositions comprising a population of alphavirus replicon particles comprising two or more isolated nucleic acids selected from 1) an isolated nucleic acid encoding an env gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a gag gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein thegag gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing thegag gene product or the immunogenic fragment thereof and their release from a cell, and 3) an isolated nucleic acid encoding a pol gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the pol gene product or immunogenic fragment thereof is modified to inhibit integrase, Rnase H and/or reverse transcriptase activity, and wherein the nucleic acids are each contained within a separate alphavirus replicon particle.
摘要翻译：本发明提供方法和组合物，其包含包含两种或更多种分离的核酸的甲型病毒复制子颗粒群，所述分离的核酸选自1）编码人免疫缺陷病毒的env基因产物或其免疫原性片段的分离的核酸，2）分离的核酸编码人免疫缺陷病毒的gag基因产物或其免疫原性片段的酸，其中修饰所述gag基因产物或其免疫原性片段以抑制含有所述gag基因产物或其免疫原性片段的病毒样颗粒及其从细胞释放的病毒样颗粒的形成和3）编码人免疫缺陷病毒的pol基因产物或其免疫原性片段的分离的核酸，其中pol基因产物或其免疫原性片段被修饰以抑制整合酶，Rnase H和/或逆转录酶活性，并且其中核酸各自包含在单独的甲病毒复制子中粒子。

2. 发明申请

WO2004000872A3 IMPROVED ALPHAVIRUS VECTORS HAVING ATTENUATED VIRION STRUCTURAL PROTEINS 审中-公开
标题翻译：具有衰减病毒结构蛋白质的改良型ALVHAVIRUS载体
公开(公告)号：WO2004000872A3
公开(公告)日：2005-02-17
申请号：PCT/US0319626
申请日：2003-06-20
申请人： UNIV NORTH CAROLINA , ALPHAVAX INC , DAVIS NANCY , WEST ANDE , JOHNSTON ROBERT E , SMITH JONATHAN
发明人： DAVIS NANCY , WEST ANDE , JOHNSTON ROBERT E , SMITH JONATHAN
IPC分类号： A61K39/12 , A61K39/145 , A61K39/193 , A61K39/21 , C07H21/04 , C07K20060101 , C12N7/04
CPC分类号： A61K39/145 , A61K39/12 , A61K39/21 , A61K2039/5254 , A61K2039/5256 , A61K2039/54 , C12N7/00 , C12N2740/16222 , C12N2740/16234 , C12N2760/16034 , C12N2770/36143 , C12N2770/36161
摘要： The present invention provides immunogenic compositions and methods that may be used to administer safer (i.e., attenuated) alphavirus vectors (such as alphavirus vectors comprising a VEE virion shell) that retain improved immunogenicity as compared with other attenuated alphaviruses (e.g., the VEE 3014 mutant, described below). In particular embodiments of the invention, the alphavirus vector comprises VEE structural proteins comprising an attenuating mutation in the E1 glycoprotein. In other particular embodiments, the attenuating mutation is in the fusogenic region of the E1 glycoprotein. The present invention enables administration of lower dosages of a safer (i.e., attenuated) virus and, thus, can further reduce manufacturing costs. The present inventors have found that immunogenicity of alphavirus vectors may be influenced by a number of factors including species, site and route of administration.
摘要翻译：本发明提供免疫原性组合物和方法，其可用于与其它减毒的甲病毒（例如，VEE 3014突变体）相比，其保持更好的（即减毒的）甲病毒载体（例如包含VEE病毒粒子的甲病毒载体），其保持改善的免疫原性，如下面所描述的）。在本发明的具体实施方案中，甲病毒载体包含包含E1糖蛋白中的减毒突变的VEE结构蛋白。在其它具体实施方案中，减毒突变位于E1糖蛋白的融合区。本发明使得能够施用较低剂量的更安全（即，减毒）的病毒，因此可以进一步降低制造成本。本发明人已经发现甲病毒载体的免疫原性可能受许多因素的影响，包括物种，部位和给药途径。

3. 发明申请

WO2004000872A9 IMPROVED ALPHAVIRUS VECTORS HAVING ATTENUATED VIRION STRUCTURAL PROTEINS 审中-公开
标题翻译：具有衰减病毒结构蛋白质的改良型ALVHAVIRUS载体
公开(公告)号：WO2004000872A9
公开(公告)日：2004-12-16
申请号：PCT/US0319626
申请日：2003-06-20
申请人： UNIV NORTH CAROLINA , ALPHAVAX INC , DAVIS NANCY , WEST ANDE , JOHNSTON ROBERT E , SMITH JONATHAN
发明人： DAVIS NANCY , WEST ANDE , JOHNSTON ROBERT E , SMITH JONATHAN
IPC分类号： A61K39/12 , A61K39/145 , A61K39/193 , A61K39/21 , C07H21/04 , C07K20060101 , C12N7/04 , C07K
CPC分类号： A61K39/145 , A61K39/12 , A61K39/21 , A61K2039/5254 , A61K2039/5256 , A61K2039/54 , C12N7/00 , C12N2740/16222 , C12N2740/16234 , C12N2760/16034 , C12N2770/36143 , C12N2770/36161
摘要： The present invention provides immunogenic compositions and methods that may be used to administer safer (i.e., attenuated) alphavirus vectors (such as alphavirus vectors comprising a VEE virion shell) that retain improved immunogenicity as compared with other attenuated alphaviruses (e.g., the VEE 3014 mutant, described below). In particular embodiments of the invention, the alphavirus vector comprises VEE structural proteins comprising an attenuating mutation in the E1 glycoprotein. In other particular embodiments, the attenuating mutation is in the fusogenic region of the E1 glycoprotein. The present invention enables administration of lower dosages of a safer (i.e., attenuated) virus and, thus, can further reduce manufacturing costs. The present inventors have found that immunogenicity of alphavirus vectors may be influenced by a number of factors including species, site and route of administration.
摘要翻译：本发明提供免疫原性组合物和方法，其可用于与其它减毒的甲病毒（例如，VEE 3014突变体）相比，其保持更好的（即减毒的）甲病毒载体（例如包含VEE病毒粒子的甲病毒载体），其保持改善的免疫原性，如下面所描述的）。在本发明的具体实施方案中，甲病毒载体包含包含E1糖蛋白中的减毒突变的VEE结构蛋白。在其它具体实施方案中，减毒突变位于E1糖蛋白的融合区。本发明使得能够施用较低剂量的更安全（即，减毒）的病毒，因此可以进一步降低制造成本。本发明人已经发现甲病毒载体的免疫原性可能受许多因素的影响，包括物种，部位和给药途径。

4. 发明申请

WO2011081723A3 PRESSURE AND FLOW CONTROL IN DRILLING OPERATIONS 审中-公开
标题翻译：钻井作业中的压力和流量控制
公开(公告)号：WO2011081723A3
公开(公告)日：2011-08-25
申请号：PCT/US2010056433
申请日：2010-11-12
申请人： HALLIBURTON ENERGY SEVICES INC , POOL CHARLES M , DAVIS NANCY , URIAS FRANK , SKINNER NEAL G
发明人： POOL CHARLES M , DAVIS NANCY , URIAS FRANK , SKINNER NEAL G
IPC分类号： E21B44/00 , E21B47/06 , E21B47/12
CPC分类号： E21B21/08 , E21B21/10
摘要： A method of maintaining a desired downhole pressure during a drilling operation can include measuring a parameter with a sensor, communicating actual parameter values from the sensor to a predictive device, training the predictive device to output predicted parameter values in response to input of the actual parameter values, and outputting the predicted parameter values from the predictive device when the predictive device ceases receiving the actual parameter values. A well drilling system can include a predictive device which outputs predicted parameter values in response to input of actual parameter values to the predictive device. The predictive device continues to output the predicted parameter values, even when the predictive device fails to receive valid actual parameter values. Another well drilling system includes a data validator which communicates valid actual parameter values to the predictive device, but does not communicate invalid actual parameter values to the predictive device.
摘要翻译：在钻井操作期间维持期望的井下压力的方法可以包括使用传感器测量参数，将来自传感器的实际参数值传达到预测装置，训练预测装置以响应于实际参数的输入来输出预测参数值值，并且当预测装置停止接收实际参数值时，从预测装置输出预测参数值。钻井系统可以包括预测装置，其响应于对预测装置的实际参数值的输入而输出预测参数值。即使预测装置未能接收到有效的实际参数值，预测装置继续输出预测的参数值。另一个钻井系统包括数据验证器，其将有效的实际参数值传达给预测装置，但不向预测装置传送无效的实际参数值。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式